ArticleBiochemistry and biophysics reports2026
Relationship between radiosensitivity of peripheral blood lymphocytes, breast cancer cells, and breast cancer stem cells in patients with breast cancer.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiosensitivity (RS) is an important biological factor that may contribute to future radiotherapy individualization. However, a comprehensive metric that adequately captures the complexities of radiation sensitivity has not yet been proposed, and the survival fraction at 2 Gy (SF2) remains the prevailing gold standard. Considerable variability in radiation responses across different cell types, together with heterogeneity within neoplastic and normal cell populations, continues to complicate radiosensitivity assessment. This study aimed to investigate the relationship between the radiosensitivity of malignant and non-malignant cells, with particular emphasis on cancer stem cells (CSCs). Blood samples and tumor biopsy specimens were collected from 20 breast cancer patients. Radiosensitivity was evaluated using clonogenic survival assays in lymphocytes, breast cancer cells, and breast cancer stem cells, while DNA damage and repair kinetics in lymphocytes were assessed using the γH2AX assay. The results showed that the geometric mean measured 30 min after radiation exposure, as well as the residual double-strand breaks (DSBs) at 3 and 24 h in the γH2AX assay, were significantly correlated with lymphocyte SF2. These findings suggest that the γH2AX assay may provide complementary information to clonogenic survival assay. However, no significant correlation was observed between the radiosensitivity of lymphocytes and that of tumor cells or CSCs. Breast cancer stem cells exhibited slightly higher survival following irradiation compared with the corresponding tumor cells, indicating a trend toward increased radioresistance. The observed radiosensitivity patterns may provide preliminary biological insights, but they should not be interpreted as direct clinical predictors without validation in larger cohorts with treatment outcome data. Further studies incorporating larger cohorts and additional biological indicators are required to improve the prediction of radiation response and clarify their potential relevance for future individualized radiotherapy research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.